IVA Inventiva SA

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of 31 December 2025:

  • Cash: € 526,751.56
  • Number of shares: 58,515 
  • Number of executions on buy side on semester: 2,332
  • Number of executions on sell side on semester: 2,741
  • Traded volume on buy side on semester: 550,198 shares for € 2,093,559.19
  • Traded volume on sell side on semester: 576,215 shares for € 2,189,327.66

At the last half-year report as of 30 June 2025 the following resources were available in the liquidity account:

  • Cash: € 428,212.57
  • Number of shares: 84,532
  • Number of executions on buy side on semester: 1,642
  • Number of executions on sell side on semester: 1,878
  • Traded volume on buy side on semester: 267,584 shares for € 744,692.94
  • Traded volume on sell side on semester: 296,504 shares for € 819,771.51

When the contract was initially implemented, the following resources were included in the liquidity account:

  • Cash: € 163,510.42
  • Number of shares: 34,063
 Buy Side Sell Side
 Number of

executions		Number of

shares		Traded volume in EUR Number of

executions		Number of

shares		Traded volume in EUR
Total2,332550,1982,093,559.19 2,741576,2152,189,327.66
07/01/2025142,6136,846.06 101,2363,275.40
07/02/2025183,3728,699.76 ---
07/03/202591,5013,977.65 498,03721,378.42
07/04/2025172,9997,917.36 25001,325.00
07/07/2025211,5164,017.40 193,3428,923.14
07/08/202548372,293.38 375,72015,730.00
07/09/2025101,7504,830.00 212,5006,975.00
07/10/202557782,155.06 101,0012,782.78
07/11/202581,6074,467.46 161,9995,597.20
07/14/2025182,8787,885.72 55501,518.00
07/15/20253252690.48 202,5006,900.00
07/16/202571,4984,149.46 131,9775,515.83
07/17/20251250695.00 101,0232,843.94
07/18/202581,0002,760.00 4240669.60
07/21/2025152,2706,197.10 1250685.00
07/22/202561,0002,750.00 273,76010,377.60
07/23/2025335,73015,757.50 356,45017,995.50
07/24/202581,7504,742.50 ---
07/25/2025--- 41,0002,780.00
07/28/2025214,75013,347.50 427,75322,173.58
07/29/20252250725.00 7511,15432,346.60
07/30/2025274,53112,958.66 101,6154,731.95
07/31/2025203,96911,192.58 254,75013,585.00
08/01/2025172,7507,755.00 71,2513,590.37
08/04/2025112,5006,950.00 51,0312,876.49
08/05/2025131,7504,935.00 121,7194,864.77
08/06/2025111,9845,555.20 193,53910,050.76
08/07/2025213,0008,700.00 223,4119,994.23
08/08/2025122,0675,932.29 212,0495,962.59
08/11/2025102,0005,840.00 212,2506,592.50
08/12/20252279825.84 283,75011,137.50
08/13/2025222,9018,993.10 669,75030,615.00
08/14/202547502,527.50 6510,99937,396.60
08/15/2025183,75012,862.50 142,0507,154.50
08/18/202537502,535.00 345,70020,406.00
08/19/2025163,25012,382.50 679,00034,740.00
08/20/2025112,5009,650.00 143,04011,825.60
08/21/2025294,10815,651.48 163,46013,390.20
08/22/2025142,99211,459.36 101,7516,811.39
08/25/202571,7506,772.50 396,75027,067.50
08/26/2025142,75011,110.00 193,25013,292.50
08/27/2025--- 7512,25054,145.00
08/28/2025204,00019,320.00 387,00034,440.00
08/29/2025286,25029,500.00 405,75027,887.50
09/01/2025366,75031,792.50 101,5007,560.00
09/02/2025163,00013,260.00 102,25010,125.00
09/03/2025--- 275,00023,400.00
09/04/20253413,00058,760.00 ---
09/05/202563,95517,599.75 22,0009,000.00
09/08/20252712,00052,320.00 710,00044,000.00
09/09/202512,0008,900.00 810,00045,500.00
09/10/2025--- 34,00018,600.00
09/11/2025--- 31,0004,750.00
09/12/202547503,487.50 ---
09/15/202532,50011,300.00 22501,195.00
09/16/202543,50015,575.00 21,0004,500.00
09/17/202567,00030,170.00 54,00017,360.00
09/18/2025--- 123,00013,560.00
09/19/2025--- 42,0009,240.00
09/22/2025162,34510,904.25 183,25015,307.50
09/23/2025295,75027,025.00 326,50030,810.00
09/24/2025305,27824,912.16 163,50016,765.00
09/25/2025--- 346,95534,427.25
09/26/2025316,75033,075.00 336,25031,000.00
09/29/2025409,50046,930.00 357,00035,280.00
09/30/2025398,00038,560.00 203,75018,337.50
10/01/2025142,75113,554.95 336,25031,270.00
10/02/2025122,75013,970.00 387,33537,921.95
10/03/2025378,00042,640.00 416,25033,625.00
10/06/2025479,25047,452.50 131,5007,755.00
10/07/2025408,24941,162.51 243,75019,387.50
10/08/2025478,72240,470.08 203,04714,503.72
10/09/20254910,90046,216.00 356,00025,620.00
10/10/2025419,25037,185.00 274,75019,380.00
10/13/2025529,90038,412.00 122,75010,917.50
10/14/2025306,50023,855.00 5612,00046,200.00
10/15/2025378,00030,880.00 133,00011,760.00
10/16/2025275,75020,757.50 265,06918,856.68
10/17/2025306,25021,625.00 214,00013,960.00
10/20/2025306,75022,545.00 133,25010,985.00
10/21/2025153,50011,550.00 162,7509,212.50
10/22/2025296,60021,054.00 92,0006,400.00
10/23/2025234,89915,039.93 194,50013,950.00
10/24/2025184,00012,280.00 173,47410,977.84
10/27/2025133,0009,210.00 447,50023,325.00
10/28/2025133,25010,562.50 7213,52644,500.54
10/29/20255212,00039,600.00 9520,18174,669.70
10/30/2025478,75530,467.40 37502,625.00
10/31/202551,2504,500.00 336,75024,435.00
11/03/2025357,29526,043.15 264,57416,740.84
11/04/2025213,00510,547.55 347,17725,837.20
11/05/2025264,60616,489.48 92,2508,190.00
11/06/2025122,0507,646.50 397,50028,350.00
11/07/2025245,34419,398.72 51,2504,650.00
11/10/2025398,49529,052.90 47502,685.00
11/11/2025122,2507,312.50 ---
11/12/202561,5005,040.00 264,50015,210.00
11/13/202592,2507,245.00 37502,430.00
11/14/202592,2507,177.50 122,5008,325.00
11/17/2025102,5008,575.00 468,00028,080.00
11/18/2025223,75012,975.00 111,5005,235.00
11/19/2025143,00010,410.00 143,50012,285.00
11/20/2025172,7509,570.00 184,25015,130.00
11/21/2025284,89517,132.50 82,0007,100.00
11/24/2025132,8009,660.00 304,00014,000.00
11/25/2025153,30712,037.48 5110,00036,900.00
11/26/20253612,00045,960.00 3411,52045,388.80
11/27/2025176,50024,245.00 309,00034,110.00
11/28/2025214,44316,261.38 15001,850.00
12/01/202562,0007,240.00 41,0003,690.00
12/02/20252812,50046,750.00 177,50028,725.00
12/03/20254814,25549,607.40 ---
12/04/2025165,50019,140.00 145,00017,550.00
12/05/2025224,50015,705.00 72,5068,821.12
12/08/202592,5008,700.00 216,91224,192.00
12/09/2025125,00017,750.00 258,08229,014.38
12/10/2025236,20622,713.96 3111,06041,475.00
12/11/2025187,00026,180.00 165,00019,000.00
12/12/202552,0007,520.00 180308.80
12/15/2025269,00033,750.00 155,50020,900.00
12/16/2025239,29433,830.16 218,00129,523.69
12/17/2025136,00022,620.00 299,35935,844.97
12/18/2025188,00030,320.00 176,94327,216.56
12/19/2025229,50034,675.00 135,00018,450.00
12/22/2025216,50023,335.00 228,00029,280.00
12/23/2025227,50028,800.00 2910,49440,821.66
12/24/2025124,35316,280.22 104,00015,160.00
12/29/2025464239.36 133,56313,681.92
12/30/202551,0003,880.00 31,5005,910.00
12/31/202551,0003,870.00 25001,960.00

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.  

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).

Contacts

Inventiva



Pascaline Clerc, PhD

EVP, External and Corporate Affairs

   

    		ICR Healthcare

Alexis Feinberg

Media Relations







 		ICR Healthcare

Patricia L. Bank

Investor Relations

          



         

Attachment



EN
26/01/2026

Underlying

IVAInventiva SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Inventiva SA

 PRESS RELEASE
Free
IVA INVENTIVA SA

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvre...

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resou...

January 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Bilan semestriel du contrat de liquidité de la société Inventiva concl...

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), New York City (New York, Etats-Unis), le 26 janvier 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique ("MASH"), annonce aujourd’hui le bilan semestriel de son contrat de liquidité conclu avec Kepler Cheuvreux. Au titre du contrat de liquidité portant sur les actions de la Société confié à Kepler Cheuvreux,...

January 26, 2026 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Confere...

Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference Daix (France), New York City (New York, United States), December 17, 2025 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to present a corporate overview, and will engage with Inventiva’s leadership team in investor meetings, at the upcoming 44th Annual J.P. Morgan Healthcare Co...

December 17, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthca...

Inventiva présentera à la 44e conférence annuelle J.P. Morgan Healthcare    Daix (France), New York City (New York, États-Unis), le 17 décembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son Directeur général, Andrew Obenshain, a été invité à présenter une vue d’ensemble de la Société et qu’il participera, aux côtés de l’équipe de direction d’Inventi...

December 17, 2025 1 EN
 PRESS RELEASE
Free
IVA INVENTIVA SA

Results of the Votes of the Combined Shareholders’ General Meeting of...

Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025 Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting.   The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur,...

November 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch